Gene and Cell Therapy Blog Archive | AGT

AGT on Social Media: David Hardy MD Senior Clinical Advisor Dr. David Hardy, MD is a nationally recognized expert in infectious diseases, with over three decades of experience in HIV research, treatment, and clinical care. He has held leadership roles in both academic medicine and the biopharmaceutical industry, contributing to the development and evaluation of numerous antiretroviral therapies a…

HIV Cure Clinical Trial Most Recent Clinical Trial Update Aug 2023 Following the Phase Ia study, we explored how the engrafted cells might impact their response to an analytic treatment interruption. To do so, we designed a follow-on study with six participants from the Phase Ia trial. This new study featured an analytical treatment interruption (ATI) where we took the participants off of their a…

AGT on Social Media: Barry H. Wells, M.D. Head of Business Development Barry H. Wells, M.D., has devoted his career to eliminating disease. After nearly four decades as a urologist and surgeon treating patients suffering from kidney stones, urinary tract infections and other urological issues, he broadened his scope to help American Gene Technologies® in its mission to use the power of gene thera…

AGT on Social Media: Robert R. Redfield, MD Special Advisor to the CEO Robert R. Redfield, MD is well known for his decades of dedicated work in virology, immunology and clinical research. He has helped lead collaborative research into HIV/AIDS since the beginning of the epidemic during his years as a U.S. Army physician and at the University of Maryland School of Medicine. Redfield, MD has held …

Jeff Galvin Is Taking a New Approach to Medicine There’s a revolution brewing in medicine, and the paradigm-shifting innovations in the gene and cell therapy space are right at the heart of the movement. Jeff Galvin, CEO of American Gene Technologies® (AGT ™) and Addimmune™, has seen firsthand what gene and cell therapies can do. With a background in economics, software and engineering he has a r…

Future Watch: Gene & Cell Therapy A Revolution In Medicine And Healthcare Blog Future Watch: Gene & Cell Therapy A Revolution In Medicine And Healthcare Blog Jeff Galvin Is Taking a New Approach to Medicine There’s a revolution brewing in medicine, and the paradigm-shifting innovations in the gene and cell therapy space are right at the heart of the movement. Jeff Galvin, CEO of American Gene Tec…

The silent HIV epidemic has been ongoing for 4 decades. AIDS-related illnesses have claimed over 32 million lives since the beginning of the HIV epidemic in 1981. The death toll, societal impact, and economic effects of the HIV epidemic have made HIV/AIDS one of the greatest public health threats the world has ever known. Governments, companies and private individuals have collectively spent tril…

Original Post in The Bay Area Reporter By: Matthew S. Bajko A new endowment named in honor of the pioneering HIV physician Dr. Marcus Conant aims to help educate future generations of health care providers interested in caring for people living with HIV and LGBTQ individuals. It has a particular focus on those entering the field of HIV dermatology, which Conant had specialized in at his now-close…

The cure for cancer is the holy grail of the medical sciences, so it may surprise you to learn that there are already two types of gene therapies that treat cancer. These cancer gene therapies are being used on multiple forms of blood cancer, and American Gene Technologies believes that there are many more cancer types which this unique therapeutic modality can address. Here, we’ll show you what …

CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune™ — a new spinoff company harnessing gene and cell therapy technologies for a potential HIV cure. Addimmune will focus solely on HIV research while building upon more than a decade of work by American Gene Technologies®. Join us as w…

American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company — Addimmune — to continue to develop gene and cell therapy technologies to cure HIV. Addimmune will focus solely on advancing an HIV cure, building upon more than a decade of work by AGT that led to a successful Phase 1 HIV gene and cell therapy clinical trial. Addimm…

There are treatments to keep HIV patients healthy and the virus at bay, but there is still no known cure. A Rockville, Maryland, company thinks it’s headed in the right direction. American Gene Technologies, a 15-year-old gene therapy biotech company with no products on the market, cites strong, positive clinical trial results for its potential HIV cure in moving to create a separate company to e…

For Jeff Galvin, the CEO and founder of newly launched Addimmune, HIV is not a condition that’s in the rearview mirror. It needs a functional cure to save lives, make people healthier and save money that need not have been spent. People wonder why it’s worth bothering to cure HIV, Galvin told BioWorld, when they are taking their medications every day and they are feeling pretty close to normal. B…

Powered by promising Phase I results from its HIV gene and cell therapy, American Gene Technologies (AGT) is spinning off a new company dedicated solely to develop a cure for a disease Chief Executive Officer Jeff Galvin calls ‘insidious.” The new company, called Addimmune, will build on the success of the Phase I trial assessing AGT’s Gag-specific AGT103-T, a genetically modified cell product th…

American Gene Technologies, a Rockville-based biotech firm, announced on Friday that it was standing up a new company to oversee its HIV treatment project, which recently completed Phase 1 of its clinical trial. "When we did the efficacy part of the Phase 1 trial, we got really encouraging data that makes us believe that we're on track for a potential solution for people that are living with HIV …

A Rockville gene therapy company is determined to find a cure for HIV — and recent studies suggest it might be on the right track. American Gene Technologies, a 15-year-old company founded and run by CEO Jeff Galvin, conducted several clinical trials with “strong, positive results” indicating a potential cure for patients diagnosed with human immunodeficiency virus (HIV), which leads to AIDS. Ame…

A Rockville-based biotech firm, American Gene Technologies (AGT), has reported promising data on its gene cell therapy for HIV cure. The treatment, which involves genetically modifying a patient’s immune cells to target and eliminate HIV-infected cells, has shown significant promise in early-stage clinical trials. According to AGT, the therapy has successfully eliminated HIV-infected cells in sev…

When Jeff Galvin founded American Gene Technologies in 2008, he envisioned a future where gene therapy could be used to write disease out of the genetic code. Today, on June 9, 2023, that future just got a lot closer with three major announcements: - The company’s HIV gene therapy, AGT103-T, has yielded encouraging data through two separate clinical studies. The trajectory projected by these data…

Have a listen. From Lab to Launch by Qualio Marcus A. Conant, MD is the Chief Medical Officer at American Gene Technologies. Dr. Conant is a physician who treated thousands of HIV patients in the early 80s while running the inpatient dermatology service at the University of California San Francisco. Before anyone recognized the virus or understood that it was about to become a global epidemic, he…

Rare disease, as the name suggests, affects a small proportion of the population and appears with low prevalence. The limited number of patients impedes development of new therapies, reducing the pool of clinical trial candidates and the size of the end market. A surprising figure is that the average rare disease has a population below 100. According to the National Institutes for Health, there a…